Oncolytics Biotech Inc T.ONC

Riovant in plans to sell UC drug to Roche for US$7 Billion

[Noteable]

July 14, 2023 - Riovant in discussions to sell its single-agent experimental ulcerative colitis drug RVT-3101 for 7 billion dollars, less than a year after acquiring the program from Pfizer.

https://www.wsj.com/articles/roivant-in-talks-to-sell-stomach-drug-to-roche-in-deal-valued-at-more-than-7-billion-c68e3f3f

https://investor.roivant.com/news-releases/news-release-details/roivant-reports-chronic-period-data-rvt-3101-tuscany-2-phase-2b

[Noteable]

Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign. https://investor.roivant.com/news-releases/news-release-details/roivant-sciences-announces-change-its-board-directors

[Noteable]

In December 2022, Riovant Sciences and Pfizer formed a subsidiary (Vant Co.) to develop biologicals, specifically the humanized monoclonal antibody targeting TL1A, now being discussed for a US$7 Billion acquisition by Roche. https://www.sec.gov/Archives/edgar/data/1635088/000114036122043937/brhc10044960_ex99-1.htm "Our internally discovered antibody against TL1A, could potentially be the

[fox7mf]

So, who's gonna pull that $15b trigger? How much will Roche spend this year? Is Merck a likely contender? Is it looking like this ends in partnership rather than b/o? Sigh....who knows?

[fasttrack5]

All good questions. only ones that would know that are the principal's of those companies. let's hope at least one pulls the trigger!

[Noteable]

" The market for UC and Crohn’s, often grouped as inflammatory bowel disease (IBD), was valued at $17.3 Billion in 2021 by Transparency Market Research. The group projected this number would rise to more than $34 billion by 2031. Growth Plus Reports puts this market value at nearly $40 Billion. " https://www.biospace.com/article/roche-in-talks-to-buy-stomach-drug-from-roivant